#United States #New York #Securities Fraud #Rosen Law Firm #Baxter International

Investors Urged to Join Baxter International Class Action

The Rosen Law Firm, widely recognized for its commitment to investor rights, has recently issued a crucial reminder for those who purchased common stock of Baxter International Inc. (NYSE: BAX) during the class period running from February 23, 2022, to July 30, 2025. This announcement carries significant implications for affected investors, as the firm notes a pressing deadline for leading plaintiffs on December 15, 2025.

Why This Matters

For individuals who bought shares of Baxter during the specified timeframe, there is a potential for compensation without incurring out-of-pocket costs, thanks to a contingency fee arrangement offered by the law firm. This means that if you are eligible, you can pursue your claim without upfront legal fees.

What Steps to Take

To participate in the class action lawsuit, affected investors are encouraged to visit the Rosen Law Firm's dedicated page for more information or to directly submit their details online. Investors can also contact Phillip Kim, Esq. at their toll-free number or via email for assistance regarding the lawsuit. The law firm has already initiated a class action, and those interested in serving as lead plaintiffs must file their motion by the upcoming deadline.

Choosing the Right Representation

Rosen Law Firm emphasizes the importance of selecting legal counsel with a proven track record in leading roles within securities litigation. Many firms may lack the necessary experience or recognition, serving more as intermediaries than advocates for investors. In contrast, Rosen Law Firm has successfully achieved substantial settlements, including the largest to date against a Chinese company, showcasing their effectiveness in navigating complex securities class actions.

Details of the Lawsuit

Central to the case are claims that Baxter misled investors by failing to disclose critical information about the Novum LVP devices during the class period. Specifically, the lawsuit outlines several alarming issues:
1. Systemic Defects: The Novum LVP reportedly suffered from defects that resulted in serious malfunctions, from underinfusions to complete failures in delivering necessary fluids.
2. Ignored Incidents: It is asserted that Baxter was aware of numerous malfunctions leading to patient injuries and even fatalities due to these defects.
3. Ineffective Remedial Actions: The attempts Baxter made to rectify the situation through customer alerts were deemed grossly inadequate, failing to address persistent design flaws.
4. Impact on Sales: These issues raised significant concerns about the company's market standing, including the risk of halting the sales of the defective pumps altogether.
5. Misleading Statements: The lawsuit argues that Baxter's claims regarding the safety, efficacy, and market potential of their products were materially false, leading to investor damages when the true state of affairs became public.

Next Steps for Investors

Investors wishing to join the class action can follow the necessary steps to sign up and secure their potential claims. However, it is essential to note that no class has yet been certified. Until such certification occurs, affected investors retain the option to choose whether they want to participate or remain absent from the class proceedings.

Investors are advised to act promptly, as the details of the class action could evolve rapidly leading up to the deadline. Keep informed and ensure your rights are protected as developments unfold.

For further updates and details, follow the Rosen Law Firm on their social media platforms including LinkedIn, Twitter, and Facebook.

Conclusion

With the deadline for lead plaintiffs approaching, Baxter International Inc. shareholders are urged to take immediate action if they wish to be part of the class action lawsuit. This pivotal moment could provide the necessary avenue for recovering losses stemming from the alleged securities fraud. Ensure you consult with knowledgeable legal counsel to navigate this process effectively.

This information is provided by the Rosen Law Firm, which specializes in investor rights advocacy.